ArticleHeliyon2024
Challenging diagnosis of primary hepatic epithelioid hemangioendothelioma in a patient with familial Mediterranean fever and hypothyroidism: A rare case report.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular tumor that accounts for less than 1 % of all vascular tumors. The diagnosis of primary hepatic epithelioid hemangioendothelioma (HEHE) can be challenging because it may be mistaken for other liver lesions. This has led to misdiagnosis in many cases. This study aimed to present a rare case of HEHE that was diagnosed in a female patient with familial Mediterranean fever (FMF) and hypothyroidism who received pazopanib treatment and demonstrated a long-term response to it. Case presentation: A 43-year-old Syrian woman with FMF who was treated with colchicine for 5 years and hypothyroidism treated with thyroxin was diagnosed with HEHE. She was treated with a tyrosine kinase inhibitor (pazopanib) for over two years and showed a durable response. Although the patient stopped taking colchicine, the episodes of abdominal pain improved after the initiation of pazopanib administration. Pazopanib was well tolerated, and the patient is still alive and doing well. Conclusions: This study highlights a case of chronic abdominal pain in a patient with multiple comorbidities that resulted in the diagnosis of a rare case of HEHE and prolonged response to pazopanib. In addition, we discuss the effects of pazopanib on FMF symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.